Welcome to Novo Nordisk in the United States

Diabetes 2025: U.S. Diabetes Prevalence, Demographics, and Cost Forecasts by State

Diabetes 2025

Novo Nordisk commissioned research that was the first to provide detailed diabetes prevalence (including demographics), and cost forecasts, individually for all 50 states. The Institute for Alternative Futures (IAF) conducted this research, and compared with a baseline in 2010, the study estimated that the overall number of people in the United States living with diabetes will increase 64% by 2025 to 53.1 million.1 The resulting medical and societal cost of diabetes will be almost $514 billion—a 72% increase from 20101 and comparable to approximately 90% of the total budget for Medicare in 2013.2

The study also found California, Texas, Florida, New York, Ohio, Illinois, Georgia, Pennsylvania, North Carolina, and Michigan as “diabetes hot spots,” where the burden of diabetes will be greatest from now until 2025. These states are projected to carry half the population burden of diabetes in the United States, with more than 50% of Americans with diabetes living in these areas.3

View the U.S. interactive map of the study’s findings for more state level information.


  1. Rowley W, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Population Health Management. 2012; DOI: 10.1089/pop.2011.0053.
  2. The Henry J. Kaiser Family Foundation. The facts on Medicare spending and financing. https://kaiserfamilyfoundation.files.wordpress.com/2014/07/7305-08-the-facts-on-medicare-spending-and-financing.pdf. Published July 28, 2014. Accessed March 30, 2015.
  3. Novo Nordisk Inc. Ten states bear brunt of diabetes burden. Press release. March 17, 2011. http://www.prnewswire.com/news-releases/ten-states-bear-brunt-of-diabetes-burden-118160629.html. Accessed April 1, 2015.

© 2016 Novo Nordisk All rights reserved. 0415-00026489-1 January 2016